Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HEC585

Small molecule · developed by Sunshine Lake Pharma Co.

Phase 3 Most advanced trial
SBFM Developer
2 Registered trials

What is HEC585?

HEC585 is an oral once-daily tablet that is being studied in progressive fibrosing interstitial lung disease and idiopathic pulmonary fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Respiratory
Developer
Sunshine Lake Pharma Co., Ltd. (SBFM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07082842 Phase 3 Idiopathic Pulmonary Fibrosis (IPF) Recruiting SBFM
NCT05139719 Phase 2 Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive… Recruiting SBFM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary Fibrosis (IPF)

More from Sunshine Lake Pharma Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.

Follow SBFM, the company behind HEC585

See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SBFM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.